No connection

Search Results

HALO vs UNH

HALO
Halozyme Therapeutics, Inc.
NEUTRAL
Price
$67.82
Market Cap
$8.03B
Sector
Healthcare
AI Confidence
85%
UNH
UnitedHealth Group Incorporated
NEUTRAL
Price
$323.48
Market Cap
$293.61B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
HALO
26.49
UNH
24.43
Forward P/E
HALO
6.92
UNH
16.08
P/B Ratio
HALO
163.82
UNH
3.11
P/S Ratio
HALO
5.75
UNH
0.66
EV/EBITDA
HALO
11.18
UNH
16.47

Profitability

Gross Margin
HALO
77.79%
UNH
18.53%
Operating Margin
HALO
56.31%
UNH
0.34%
Profit Margin
HALO
22.69%
UNH
2.69%
ROE
HALO
153.59%
UNH
12.54%
ROA
HALO
22.24%
UNH
3.9%

Growth

Revenue Growth
HALO
51.6%
UNH
12.3%
Earnings Growth
HALO
--
UNH
-99.9%

Financial Health

Debt/Equity
HALO
44.6
UNH
0.82
Current Ratio
HALO
4.66
UNH
0.79
Quick Ratio
HALO
3.3
UNH
0.7

Dividends

Dividend Yield
HALO
--
UNH
2.73%
Payout Ratio
HALO
0.0%
UNH
65.99%

AI Verdict

HALO NEUTRAL

HALO presents a stark contrast between operational efficiency and valuation sanity. While the Piotroski F-Score of 4/9 indicates stable financial health, the stock trades at a massive premium to its Graham Number ($4.88) and Intrinsic Value ($17.92). Despite exceptional operating margins (56.31%) and strong revenue growth (51.6%), the recent collapse in EPS (-114% Q/Q) and aggressive insider selling by the CEO and COO create significant headwinds that offset the bullish analyst consensus.

Strengths
Exceptional profitability with 77.79% gross margins and 56.31% operating margins
Strong top-line momentum with 51.60% YoY revenue growth
Very high Return on Equity (153.59%) indicating efficient capital use
Risks
Extreme valuation disconnect with a Price/Book ratio of 163.82
Severe recent earnings deterioration (EPS growth -122.6% YoY)
Bearish insider sentiment with significant selling by the CEO and COO
UNH NEUTRAL

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.

Strengths
Strong consistent revenue growth (12.3% YoY)
Manageable Debt/Equity ratio of 0.82
Attractive Forward P/E (16.08) compared to current P/E (24.43)
Risks
Extreme earnings volatility (YoY Earnings Growth -99.9%)
Poor liquidity indicated by a Current Ratio of 0.79
Extremely thin operating margins (0.34%)

Compare Another Pair

HALO vs UNH: Head-to-Head Comparison

This page compares Halozyme Therapeutics, Inc. (HALO) and UnitedHealth Group Incorporated (UNH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile